Open AccessQuantitative assessment of minimal effective concentration of erythropoiesis‐stimulating agents
Author(s) -
Yan X,
Krzyzanski W
Publication year - 2013
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1038/psp.2013.39
Subject(s) - erythropoietin , erythropoiesis , pharmacodynamics , pharmacokinetics , pharmacology , in vivo , dosing , medicine , darbepoetin alfa , chemistry , anemia , biology , microbiology and biotechnology
Minimal effective concentration (MEC) was proposed to explain why subcutaneous (SC) administration of erythropoietin (EPO) induces a higher hemoglobin (HGB) increase than intravenous (IV) administration. It has been further used to explain the paradox that erythropoiesis‐stimulating agent (ESA) with lower receptor binding affinity may have higher in vivo activity. We have developed a pharmacokinetic and pharmacodynamic (PK/PD) model with incorporation of the operational model of agonism to characterize the data from two clinical trials. By using model‐based simulations, we demonstrate that SC route is more efficacious than IV route and explain the paradoxical behavior of ESAs. We determined that MEC can be quantified by C 50 , which represents the concentration of an ESA producing its half‐maximal effect of stimulating the proliferation of erythroid precursor cells. The model used may allow joint PK/PD modeling of data from different ESAs, and provide a platform for dosing regimen optimizations and future clinical study designs. CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e62; doi: 10.1038/psp.2013.39 ; published online 7 August 2013